Level A· Stronger Clinical EvidenceMeta-analysis

Type 2 Diabetes Mellitus Induced Paracrine Effects on Breast Cancer Metastasis Through Extracellular Vesicles Derived from Human Mesenchymal Stem Cells.

Khanh VC., Fukushige M., Moriguchi K., Yamashita T., Osaka M., Hiramatsu Y.

Meta-analysis on Type 2 Diabetes, published in Stem Cells Dev (2020) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type: Meta-analysis
Journal: Stem Cells Dev (2020)
Country: United States
Reported sample size: —
PMID: 32900278
DOI: 10.1089/scd.2020.0126

Abstract (original English)

Cancer metastasis is the leading cause of mortality among breast cancer patients. Type 2 diabetes mellitus (T2DM) has been suggested as a risk factor of breast cancer; however, whether or not T2DM is associated with breast tumor metastasis remains unclear. In this study, we examined the involvement of T2DM with breast cancer metastasis by a combined approach of a meta-analysis and experimental research. The results of a systematic review and meta-analysis suggested that diabetes significantly increases the risk of lymph node metastasis by 1.10-fold ( P < 0.01). Consistently, our data from experimental research showed that T2DM induced paracrine effects of mesenchymal stem cells (MSCs), a key contributor to cancer progression, to stimulate metastasis of breast cancer cells (BCCs) by two independent mechanisms. First, T2DM induced the excess secretion of interleukin 6 (IL6) from MSCs, which activated the JAK/STAT3 pathway in BCCs, thus promoting the metastasis of BCCs. Second, beside the EGR-1-/IL6-dependent mechanism, T2DM altered the functions of MSC-derived extracellular vesicles (EVs), which are highly associated with the metastasis of BCCs. Our present study showed that T2DM is a risk factor for breast cancer metastasis, and MSC-derived EVs might be useful for developing a novel anti-breast cancer therapy strategy.

What this study does not prove

• This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence

Adipose TissueAnimalsBreast NeoplasmsCell Line, TumorCell MovementDiabetes Mellitus, Type 2Early Growth Response Protein 1Extracellular VesiclesFemaleHumans

Systemic / IV Type 2 Diabetes

View on PubMed DOI

Type 2 Diabetes Mellitus Induced Paracrine Effects on Breast Cancer Metastasis Through Extracellular Vesicles Derived from Human Mesenchymal Stem Cells.

Abstract (original English)

What this study does not prove

Evidence level

Related research

Systematic Review: Exosomes as Molecular Messengers in the Development of Obesity-Related Complications in Children.

Adipose-derived Mesenchymal Stem Cells in the Treatment of Obesity: A Systematic Review of Longitudinal Studies on Preclinical Evidence.

Metabolic effects of large-volume liposuction for obese healthy women: a meta-analysis of fasting insulin levels.

Safety and efficacy of autologous adipose tissue-derived stem cell transplantation in aging-related low-grade inflammation patients: a single-group, open-label, phase I clinical trial.

Using adipose-derived mesenchymal stem cells to fight the metabolic complications of obesity: Where do we stand?

The possible role of visceral fat in early pregnancy as a predictor of gestational diabetes mellitus by regulating adipose-derived exosomes miRNA-148 family: protocol for a nested case-control study in a cohort study.